Skip to main content
. 2021 Jan 13;42(10):1653–1664. doi: 10.1038/s41401-020-00578-0

Fig. 2. SOMCL-17-016 dose-dependently prevented arthritis progression in CIA mice.

Fig. 2

a Experimental design of CIA induction and the treatment strategy. b Mice were orally treated with ibrutinib, acalabrutinib or different doses of SOMCL-17-016 for 15 days. Arthritis clinical scores were recorded every day after administration. c, d The thickness of right and left paw swelling was measured at the end of the study (n = 8 or 9). e Representative photographs displaying the gross features of the left hind paws. f Representative ankle joint sections stained with H&E (magnification of ×100). g Histopathological evaluation of the ankle joint for the presence of pannus formation, cellular infiltration, synovial proliferation, and cartilage erosion (n = 4). The data are shown as the means ± SEMs; *P < 0.05, **P < 0.01 and ***P < 0.001, #P < 0.05, ##P < 0.01, and ###P < 0.001, ∆P < 0.05, ∆∆P < 0.01, and ∆∆∆P < 0.001; SOMCL-17-016, acalabrutinib and ibrutinib respectively, significantly different from the vehicle-treated group.